Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02578277 | Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates | PHASE1 | COMPLETED | 59 | — | — | Nov 9, 2015 | Dec 23, 2015 | Jul 13, 2018 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Single sequence, 3-period DDI (drug-drug interaction) | EXPERIMENTAL | Single sequence |
| Name | Type | Description |
|---|---|---|
| CYP and transporter probe substrates | DRUG | Cocktail of CYP (cytochrome P450) and transporter probe substrates |
| BMS-955176 | DRUG | BMS-955176 |
| BMS-955176 plus CYP and transporter probe substrates | DRUG | BMS-955176 plus the cocktail of CYP and transporter probe substrates |
Inclusion Criteria: 1. Written Informed Consent 2. Healthy male and female (not of childbearing potential) subjects as determined by medical history, surgical history, physical examination, vital signs, ECGs, and clinical laboratory determinations 3. Body mass index (BMI) of 18.0 kg/m2 to 32.0 kg/m...